低密度脂蛋白在肺动脉高压中作用的研究进展
摘要
病，表现为肺血管阻力增加、肺动脉压力升高，最终导致右心衰竭和死亡。有研究观察到PAH患者血浆中Ox-LDL/
LDL比值增加，同时研究者评估了肺Ox-LDL免疫标记信号强弱，发现PAH肺血管周围区域和巨噬细胞中Ox-LDL
总体增加。LDL为人所熟知的主要作用是将胆固醇从血液运送到外周组织，通过与低密度脂蛋白受体（Low density
lipoprotein receptor，LDLR）结合，将胆固醇从血液中清除，这叫做胆固醇的逆向运输。除此之外，还发现LDL具有
以下这些功能，包括促炎、导致血栓形成、引起氧化应激等。了解这些特殊作用，有助于更好研究低密度脂蛋白与
肺动脉高压的发生、发展关系以及它如何影响疾病预后。该文回顾该领域的相关文献，对低密度脂蛋白在肺动脉高
压发生发展中的作用进行综述，以期为PAH的治疗和预后提供新思路。
关键词
全文:
PDF参考
[1]HOEPER M M, GHOFRANI H-A, GRüNIG E,
et al. Pulmonary Hypertension [J]. Dtsch Arztebl Int, 2017,
114(5): 73-84.
[2]HANSMANN G. Pulmonary Hypertension in
Infants, Children, and Young Adults [J]. J Am Coll Cardiol,
2017, 69(20): 2551-69.
[3]HUANG J, AN Q, ZHANG C-L, et al. Decreased
low-density lipoprotein and the presence of pulmonary
arterial hypertension among newly diagnosed drug-naïve
patients with systemic lupus erythematosus: D-dimer as a
mediator [J]. Exp Ther Med, 2022, 24(3): 595.
[4]UMAR S, RUFFENACH G, MOAZENI S, et al.
Involvement of Low-Density Lipoprotein Receptor in the
Pathogenesis of Pulmonary Hypertension [J]. J Am Heart
Assoc, 2020, 9(2): e012063.
[5]DI L, MAISEYEU A. Low-density lipoprotein
nanomedicines: mechanisms of targeting, biology, and
theranostic potential [J]. Drug Deliv, 2021, 28(1): 408-21.
[6]OLSON R E. Discovery of the lipoproteins, their
role in fat transport and their significance as risk factors [J]. J
Nutr, 1998, 128(2 Suppl): 439S-43S.
[7]RUDEL L L, KESäNIEMI Y A. Low-density
lipoprotein particle composition: what is the contribution to
atherogenicity? [J]. Curr Opin Lipidol, 2000, 11(3): 227-8.
[8]米春芳，刘庆平.血浆低密度脂蛋白和高密度脂
蛋白亚组分的临床意义及检测研究进展[J].中国动脉硬化
杂志，2017，25（10）：1054-60.
[9]LOREGGER A, NELSON J K, ZELCER N.
Assaying Low-Density-Lipoprotein (LDL) Uptake into Cells
[J]. Methods Mol Biol, 2017, 1583: 53-63.
[10]SEVANIAN A, ASATRYAN L, ZIOUZENKOVA
O. Low density lipoprotein (LDL) modification: basic
concepts and relationship to atherosclerosis [J]. Blood Purif,
1999, 17(2-3): 66-78.
[11]DESROCHES S, LAMARCHE B. Diet and lowdensity lipoprotein particle size [J]. Curr Atheroscler Rep,
2004, 6(6): 453-60.
[12]ALIZADEH-FANALOU S, NAZARIZADEH
A, ALIAN F, et al. Small dense low-density lipoproteinlowering agents [J]. Biol Chem, 2020, 401(10): 1101-21.
[13]NIMPF J, SCHNEIDER W J. From cholesterol
transport to signal transduction: low density lipoprotein
receptor, very low density lipoprotein receptor, and
apolipoprotein E receptor-2 [J]. Biochim Biophys Acta, 2000,
1529(1-3): 287-98.
[14]SIRTORI C R, FUMAGALLI R. LDL-cholesterol
lowering or HDL-cholesterol raising for cardiovascular
prevention. A lesson from cholesterol turnover studies and
others [J]. Atherosclerosis, 2006, 186(1): 1-11.
[15]ALIZADEH-FANALOU S, NAZARIZADEH
A, ALIAN F, et al. Small dense low-density lipoproteinlowering agents [J]. Biol Chem, 2020, 401(10): 1101-21.
[16]SPENGEL F A, THOMPSON G R. Receptormediated low-density lipoprotein catabolism [J]. Klin
Wochenschr, 1982, 60(7): 319-25.
[17]李怡华，杜郁，洪斌.低密度脂蛋白受体表达调
控的研究进展[J].中国医药生物技术，2020，15（06）：
615-22.
[18]HU Y, CHI L, KUEBLER W M, et al. Perivascular
Inflammation in Pulmonary Arterial Hypertension [J]. Cells,
2020, 9(11).
[19]VARGA J, PALINKAS A, LAJKO I, et al.
Pulmonary Arterial Pressure Response During Exercise in
COPD: A Correlation with C-Reactive Protein (hsCRP) [J].
Open Respir Med J, 2016, 10.
[20]KOPEĆ G, WALIGóRA M, TYRKA A, et
al. Low-density lipoprotein cholesterol and survival in
pulmonary arterial hypertension [J]. Sci Rep, 2017, 7: 41650.
[21]OBAMA T, ITABE H. Neutrophils as a Novel
Target of Modified Low-Density Lipoproteins and an
Accelerator of Cardiovascular Diseases [J]. Int J Mol Sci, 2020,
21(21).
[22]LIU P, ZHU W, CHEN C, et al. The mechanisms
of lysophosphatidylcholine in the development of diseases [J].
Life Sci, 2020, 247: 117443.
[23]OGURA S, SHIMOSAWA T, MU S, et al.
Oxidative stress augments pulmonary hypertension in
chronically hypoxic mice overexpressing the oxidized LDL
receptor [J]. Am J Physiol Heart Circ Physiol, 2013, 305(2):
H155-H62.
[24]ZHANG W, ZHU T, WU W, et al. LOX-1
mediated phenotypic switching of pulmonary arterial smooth
muscle cells contributes to hypoxic pulmonary hypertension
[J]. Eur J Pharmacol, 2018, 818: 84-95.
[25]DING W Y, PROTTY M B, DAVIES I G, et al.
Relationship between lipoproteins, thrombosis, and atrial
fibrillation [J]. Cardiovasc Res, 2022, 118(3): 716-31.
[26]HSU S H-J, JANG M-H, TORNG P-L, et al.
Positive Association Between Small Dense Low-Density
Lipoprotein Cholesterol Concentration and Biomarkers of
Inflammation, Thrombosis, and Prediabetes in Non-Diabetic
Adults [J]. J Atheroscler Thromb, 2019, 26(7): 624-35.
[27]QI Z, HU L, ZHANG J, et al. PCSK9 (Proprotein
Convertase Subtilisin/Kexin 9) Enhances Platelet Activation,
Thrombosis, and Myocardial Infarct Expansion by Binding to
Platelet CD36 [J]. Circulation, 2021, 143(1): 45-61.
[28]LANNAN K L, PHIPPS R P, WHITE R J.
Thrombosis, platelets, microparticles and PAH: more than a
clot [J]. Drug Discov Today, 2014, 19(8): 1230-5.
[29]OBERMAYER G, AFONYUSHKIN T, BINDER
C J. Oxidized low-density lipoprotein in inflammation-driven
thrombosis [J]. J Thromb Haemost, 2018, 16(3): 418-28.
[30]RELOU I A M, HACKENG C M, AKKERMAN J
W N, et al. Low-density lipoprotein and its effect on human
blood platelets [J]. Cell Mol Life Sci, 2003, 60(5): 961-71.
[31]BADIMóN L, VILAHUR G, PADRó T.
Lipoproteins, platelets and atherothrombosis [J]. Rev Esp
Cardiol, 2009, 62(10): 1161-78.
[32]SHAH A J, VORLA M, KALRA D K. Molecular
Pathways in Pulmonary Arterial Hypertension [J]. Int J Mol
Sci, 2022, 23(17).
[33]XU D, HU Y-H, GOU X, et al. Oxidative
Stress and Antioxidative Therapy in Pulmonary Arterial
Hypertension [J]. Molecules, 2022, 27(12).
[34]LIU Y, CHEN X, LI J. Resveratrol protects
against oxidized low‑density lipoprotein‑induced human
umbilical vein endothelial cell apoptosis via inhibition of
mitochondrial‑derived oxidative stress [J]. Mol Med Rep,
2017, 15(5): 2457-64.
[35]ZMIJEWSKI J W, MOELLERING D R, LE
GOFFE C, et al. Oxidized LDL induces mitochondrially
associated reactive oxygen/nitrogen species formation in
endothelial cells [J]. Am J Physiol Heart Circ Physiol, 2005,
289(2): H852-H61.
[36]TANG Y, ZHAO J, SHEN L, et al. ox-LDL
induces endothelial dysfunction by promoting Arp2/3
complex expression [J]. Biochem Biophys Res Commun,
2016, 475(2): 182-8.
[37]GALLE J, HANSEN-HAGGE T, WANNER C, et
al. Impact of oxidized low density lipoprotein on vascular cells
[J]. Atherosclerosis, 2006, 185(2): 219-26.
Refbacks
- 当前没有refback。
